



04-07-04

427.057-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
CHABRIER DE LASSAUNIERE et al :
Serial No.: 10/681,002 : Group: 1614
Filed: October 8, 2003 :
For: PRODUCTION...MEDICAMENTS :

475 Park Avenue South
New York, N.Y. 10016
April 5, 2004

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Applicants are returning herewith the filing receipt for the above application and ask that the Patent Office issue a corrected filing receipt. The correct spelling of the town for the fourth inventor is AUFFARGIS and not Auffargds. The correct spelling of the fifth inventor's last name is POMMIER and not Pummifr. The last name of the last inventor is THURIEAU and not Thurieanu.

"Express Mail" mailing label No. 96819757045
Date of Deposit April 5, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service, Mail Post Office to Addressee" service 27.C.3 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
Shaloung

Respectfully submitted,
Muserlian, Lucas and Mercanti

Charles A. Muserlian
Charles A. Muserlian, 19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosure



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/681,002	10/08/2003	1614	1662	427.057-1		48	6

20311
 MUSERLIAN AND LUCAS AND MERCANTI
 475 PARK AVENUE SOUTH
 NEW YORK, NY 10016

RECEIVED
 MAR 31 2004

CONFIRMATION NO. 7432

UPDATED FILING RECEIPT



OC000000012217379

MUSERLIAN, LUCAS AND MERCANTI LLP

Date Mailed: 03/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Pierre-Etienne Chabrier De Lassauniere, Paris;
 Jeremiah Harnett, Gif-Sur-Yvette, FRANCE;
 Dennis Bigg, Gif-Sur-Yvette, FRANCE;
 Anne-Marie Liberatore, Auffargds, FRANCE;
 Jacques Pummifr, Paris, FRANCE;
 Jacques Lannoy, Blevres, FRANCE;
 Christophe Thurieanu, Paris, FRANCE;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/089,993 04/04/2002
 which is a 371 of PCT/FR00/02805 10/10/2000

Foreign Applications

FRANCE 99 12643 10/11/1999
 FRANCE 00/10151 08/01/2000
 FRANCE 00/11169 09/01/2000
 JAPAN 01/04943 04/10/2001
 JAPAN 02/01811 02/14/2002

If Required, Foreign Filing License Granted: 01/09/2004

Projected Publication Date: 07/08/2004

Non-Publication Request: No

Early Publication Request: No

Title

Derivatives of heterocycles with 5 members, their preparation and their use as medicaments

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).